ArticleExperimental and therapeutic medicine2026
Genetic etiology and phenotypic characteristics of fetuses with 11q deletion syndrome (11q23.3-q25).
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 11q deletion (11q-) syndrome is a rare consecutive polygenic deletion disorder. Characterization of the clinical features, genetic etiology and diagnostic strategies associated with 11q deletion syndrome in the prenatal setting is important to understand this syndrome in its entirety. A retrospective review at Longgang District Maternity & Child Healthcare Hospital of Shenzhen City (Shenzhen, China) involving four fetuses diagnosed with 11q- syndrome was conducted to examine the clinical features of this syndrome. The cases were identified through prenatal screening, including maternal serum biochemistry, non-invasive prenatal screening (NIPS), chromosomal microarray analysis (CMA) and karyotyping. Pregnant women with high-risk results from NIPS or prenatal serological screening received early interventional prenatal diagnosis and genetic counseling. Of the two cases that showed a high-risk of 11q- by NIPS, invasive diagnostic procedures confirmed the presence of large terminal deletions on chromosome 11q, encompassing telomeric regions. CMA identified the deletions while karyotyping revealed underlying structural rearrangements, including balanced translocations in both cases. Prenatal ultrasound identified cardiac anomalies, such as ventricular septal defects and truncus arteriosus. The variability and incomplete penetrance of these malformations suggest the influence of polygenic (e.g., modifier genes, genetic background, copy number variations), epigenetic (e.g., DNA methylation, histone modification) and environmental factors (e.g., diet, lifestyle, exposure to toxins). The results demonstrated that the phenotypic expression of 11q- syndrome varies according to the size and gene content of the deleted region. The integration of CMA and karyotyping improves diagnostic accuracy and elucidates the origin of chromosomal alterations. In the single case present in the current study that involved a parental chromosomal translocation, karyotyping was essential for determining the risk of recurrence. These findings contribute to a more precise understanding of genotype-phenotype associations and support the provision of informed prenatal counseling and the clinical management of 11q- syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.